Does the Form 4 state the price ranges for the ICUI share sales?

Yes. Footnotes disclose that the shares were sold in multiple transactions with price ranges of $167.20–$168.145, $168.21–$169.15, $169.50–$169.665, and $170.775–$171.69 per share, and offer more detail on request.

ICU Medical counsel sells 4,856 shares in plan

Q: At what prices were the ICUI shares sold in this Form 4?

The reported weighted average prices were $167.667, $168.4352, $169.5255, and $171.515 per share, with detailed price ranges from about $167.20 up to $171.69 as disclosed in the footnotes.

Q: How many ICUI shares did the insider sell in each reported transaction?

Virginia Ruth Sanzone sold 2,202 shares, 1,238 shares, 724 shares, and 692 shares of ICU Medical common stock, all on September 3, 2026, for a total of 4,856 shares sold.

ICUI’s vice president and general counsel disclosed pre-planned sales totaling 4,856 common shares under a Rule 10b5-1 trading plan.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

ICU MEDICAL INC/DE (ICUI) reported that Virginia Ruth Sanzone, its VP, General Counsel, sold a total of 4,856 shares of common stock on September 3, 2026 in four open-market or private transactions pursuant to a Rule 10b5-1 trading plan adopted on June 8, 2026, at weighted average prices ranging from about $167.67 to $171.52 per share.

Insider Trade Summary 10b5-1

Net Seller: 4,856 shares

Net Sell 4 txns

Insider Sanzone Virginia Ruth

Role VP, General Counsel

Sold 4,856 shs ($819K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F2}	2,202	$167.667	$369K
Sale	Common Stock ^{F1, F3}	1,238	$168.4352	$209K
Sale	Common Stock ^{F1, F4}	724	$169.5255	$123K
Sale	Common Stock ^{F1, F5}	692	$171.515	$119K

Holdings After Transaction: Common Stock — 14,604 shares (Direct)

Footnotes (5)

F1. The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2026.
F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.20 to $168.145, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.21 to $169.15, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.5 to $169.665, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.775 to $171.69, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Key Figures

Total shares sold: 4,856 shares First tranche: 2,202 shares at $167.667 per share Second tranche: 1,238 shares at $168.4352 per share +4 more

7 metrics

Total shares sold 4,856 shares Common stock sales by VP, General Counsel on September 3, 2026

First tranche 2,202 shares at $167.667 per share Common stock sale on September 3, 2026

Second tranche 1,238 shares at $168.4352 per share Common stock sale on September 3, 2026

Third tranche 724 shares at $169.5255 per share Common stock sale on September 3, 2026

Fourth tranche 692 shares at $171.515 per share Common stock sale on September 3, 2026

Rule 10b5-1 plan adoption date June 8, 2026 Trading plan governing the reported sales

Price ranges disclosed $167.20–$171.69 per share Ranges for multiple transactions underlying the weighted average prices

Key Terms

Rule 10b5-1 trading plan, weighted average price, restricted award sales, reporting person

4 terms

Rule 10b5-1 trading plan regulatory

"sales were effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

restricted award sales financial

"The restricted award sales reported in this Form 4 were effected"

reporting person regulatory

"The reporting person undertakes to provide ICU Medical, Inc."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ICUI report in this Form 4?

ICU Medical (ICUI) reported that VP, General Counsel Virginia Ruth Sanzone sold 4,856 shares of common stock on September 3, 2026 in four reported transactions under a pre-arranged Rule 10b5-1 trading plan.

At what prices were the ICUI shares sold in this Form 4?

The reported weighted average prices were $167.667, $168.4352, $169.5255, and $171.515 per share, with detailed price ranges from about $167.20 up to $171.69 as disclosed in the footnotes.

How many ICUI shares did the insider sell in each reported transaction?

Virginia Ruth Sanzone sold 2,202 shares, 1,238 shares, 724 shares, and 692 shares of ICU Medical common stock, all on September 3, 2026, for a total of 4,856 shares sold.

Were the ICUI insider sales made under a Rule 10b5-1 plan?

Yes. The filing states the restricted award sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2026, and the Form 4 affirms the Rule 10b5-1 checkbox.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/03/2026 - 06:32 PM EDT Accepted by SEC EDGAR 09/03/2026 - 06:29 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sanzone Virginia Ruth

(Last)

(First)

(Middle)

951 CALLE AMANECER

(Street)

SAN CLEMENTE

CALIFORNIA

92673

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ICU MEDICAL INC/DE [ ICUI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	VP, General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/03/2026		S		2,202⁽¹⁾	D	$167.667⁽²⁾	17,258	D
Common Stock	09/03/2026		S		1,238⁽¹⁾	D	$168.4352⁽³⁾	16,020	D
Common Stock	09/03/2026		S		724⁽¹⁾	D	$169.5255⁽⁴⁾	15,296	D
Common Stock	09/03/2026		S		692⁽¹⁾	D	$171.515⁽⁵⁾	14,604	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.20 to $168.145, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.21 to $169.15, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.5 to $169.665, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.775 to $171.69, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

	By: Paula Darbyshire, Attorney-in-Fact For: Virginia Sanzone	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR